Jun Liu
Jun Liu has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Gongqi Li
Department of Clinical Laboratory, Linyi Traditional Hospital, Linyi, Shandong 276003, P.R. China
3 shared publicationsRenjing Hu
Department of Laboratory Medicine, the Affiliated Wuxi No. 2 People's Hospital of Nanjing Medical University, Wuxi, China
3 shared publicationsFan Tu
Department of Laboratory Medicine, Affiliated Wuxi Fifth Hospital of Jiangnan University, The Fifth People’s Hospital of Wuxi
2 shared publicationsHao Pei
Department of Laboratory Medicine, Wuxi Fifth People's Hospital, Jiangsu, China
2 shared publications- Hao Yu
Department of Interventional Oncology, Wuxi Fifth People's Hospital, Jiangsu, China
2 shared publications Shiliang Zhang
Department of Laboratory Medicine, Wuxi Fifth People's Hospital, Jiangsu, China
2 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1866051
Population-level and longitudinal MIC distributions for antimicrobials against drug-resistant Mycobacterium tuberculosis in Wuxi, a low-epidemic city in China, from 2019 to 2023
Background: Drug-resistant tuberculosis (DR-TB) remains a significant global health challenge, with increasing resistance to both first- and second-line anti-tuberculosis drugs. Understanding the demographic distribution, temporal trends, and resistance profiles of DR-TB is essential for improving treatment strategies and public health interventions. Objective: This study aimed to examine the demographic characteristics, temporal distribution, and minimum inhibitory concentration (MIC) patterns of drug-resistant Mycobacterium tuberculosis ( M. tuberculosis ) isolates in a retrospective cohort of patients with culture-confirmed DR-TB from August 2019 to July 2023. Methods: A total of 402 drug-resistant M. tuberculosis isolates from clinical patients were included in this study for the analysis of MIC distributions and resistance trends over time. The study included four DR-TB categories: isoniazid-resistant TB, RR-TB, MDR-TB, and pre-XDR-TB. No XDR-TB cases were identified. The temporal distribution of cases was analyzed for seasonal trends, and MIC values were assessed for anti-tuberculosis drugs. A longitudinal analysis was conducted to observe variations in MICs over time. Specifically, a longitudinal comparison was performed on paired M. tuberculosis isolates from 49 patients, with isolates collected at intervals exceeding 4 weeks. Results: The majority of patients were male (72.14%), and the most common form of DR-TB was isoniazid-resistant TB (23.14%). The study found significant seasonal variation, with higher DR-TB incidence in winter and spring months, and the temporal distribution was affected by COVID-19. Resistance rates were highest for isoniazid (40.30%), cycloserine (47.76%), and para-aminosalicylic acid (52.24%). Across the DR-TB cohorts, MICs for isoniazid, ethionamide, para-aminosalicylic acid, and amikacin demonstrated a significant upward trend, whereas a declining pattern was observed for ethambutol. The longitudinal comparison of paired M. tuberculosis isolates from 49 patients, demonstrated a marked elevation in the MICs for all 12 antimicrobials over the course of treatment. Conclusion: This study highlights the increasing burden of DR-TB, with increasing MICs and relatively high resistance rates for a few key drugs indicating reduced drug susceptibility over time. The increasing MICs highlight the need for continuous resistance monitoring and enhanced DR-TB control efforts.
- 8 July 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1866051
Open AccessPopulation-level and longitudinal MIC distributions for antimicrobials against drug-resistant Mycobacterium tuberculosis in Wuxi, a low-epidemic city in China, from 2019 to 2023
Background: Drug-resistant tuberculosis (DR-TB) remains a significant global health challenge, with increasing resistance to both first- and second-line anti-tuberculosis drugs. Understanding the demographic distribution, temporal trends, and resistance profiles of DR-TB is essential for improving treatment strategies and public health interventions. Objective: This study aimed to examine the demographic characteristics, temporal distribution, and minimum inhibitory concentration (MIC) patterns of drug-resistant Mycobacterium tuberculosis ( M. tuberculosis ) isolates in a retrospective cohort of patients with culture-confirmed DR-TB from August 2019 to July 2023. Methods: A total of 402 drug-resistant M. tuberculosis isolates from clinical patients were included in this study for the analysis of MIC distributions and resistance trends over time. The study included four DR-TB categories: isoniazid-resistant TB, RR-TB, MDR-TB, and pre-XDR-TB. No XDR-TB cases were identified. The temporal distribution of cases was analyzed for seasonal trends, and MIC values were assessed for anti-tuberculosis drugs. A longitudinal analysis was conducted to observe variations in MICs over time. Specifically, a longitudinal comparison was performed on paired M. tuberculosis isolates from 49 patients, with isolates collected at intervals exceeding 4 weeks. Results: The majority of patients were male (72.14%), and the most common form of DR-TB was isoniazid-resistant TB (23.14%). The study found significant seasonal variation, with higher DR-TB incidence in winter and spring months, and the temporal distribution was affected by COVID-19. Resistance rates were highest for isoniazid (40.30%), cycloserine (47.76%), and para-aminosalicylic acid (52.24%). Across the DR-TB cohorts, MICs for isoniazid, ethionamide, para-aminosalicylic acid, and amikacin demonstrated a significant upward trend, whereas a declining pattern was observed for ethambutol. The longitudinal comparison of paired M. tuberculosis isolates from 49 patients, demonstrated a marked elevation in the MICs for all 12 antimicrobials over the course of treatment. Conclusion: This study highlights the increasing burden of DR-TB, with increasing MICs and relatively high resistance rates for a few key drugs indicating reduced drug susceptibility over time. The increasing MICs highlight the need for continuous resistance monitoring and enhanced DR-TB control efforts.
- Open Access
- 1 December 2021
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 27, 63-66
Characterisation of blaNDM-5 and blaKPC-2 co-occurrence in K64-ST11 carbapenem-resistant Klebsiella pneumoniae
- 1 December 2021
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 27, 63-66
Open AccessCharacterisation of blaNDM-5 and blaKPC-2 co-occurrence in K64-ST11 carbapenem-resistant Klebsiella pneumoniae
- Open Access
- 7 September 2021
- Published by Association of Basic Medical Sciences of FBIH in Bosnian Journal of Basic Medical Sciences
- Vol. 22 (3) , 453-459
Plasma exosome-derived fragile-site associated tumor suppressor is a powerful predictor of prognosis in patients with ovarian cancer
Objective: To investigate the levels of plasma exosome-derived fragile-site associated tumor suppressor (FATS) and evaluate its predictive ability in ovarian cancer (OC) patients. Patients and Methods: Exosome-rich fractions were isolated from the plasma of enrolled 90 patients with OC. The levels of plasma exosome-derived FATS were detected with ELISA. Results: The levels of exosome-derived FATS in OC patient were significantly lower than in healthy controls (P < 0.001). The levels of plasma exosome-derived FATS were obviously higher in OC patients with low grade (1/2), FIGO stages I/II than high grade (3/4), stages III/ IV disease (P = 0.003; P < 0.001). The levels of plasma exosome-derived FATS were significantly higher in OC patients with no lymph node metastasis, no ascites than those with lymph node metastasis, ascites (both P < 0.001). The levels of plasma exosome-derived FATS were obviously higher in OC patients with CA-125 less than 35U/ml than more than 35U/ml (P < 0.001). Among all enrolled OC patients, both 5-DFS and 5-OS were shorter in patients who had low plasma exosome-derived FATS levels than that high levels (both P < 0.001). The AUROC of plasma exosome-derived FATS were 0.85(95% CI: 0.76-0.91) for 5-DFS, 0.91(95% CI: 0.83-0.96) for 5-OS prediction in patients with OC, respectively. Conclusions: Plasma exosome-derived FATS levels in OC patient were significantly down-regulated. Low levels of plasma exosome-derived FATS had close relationship with FIGO stages I/II, low grade, ascites, higher levels of CA-125, lymph node metastasis and prognosis of OC patients. Our findings may provide a new strategy in treating OC.
- 7 September 2021
- Published by Association of Basic Medical Sciences of FBIH in Bosnian Journal of Basic Medical Sciences
- Vol. 22 (3) , 453-459
Open AccessPlasma exosome-derived fragile-site associated tumor suppressor is a powerful predictor of prognosis in patients with ovarian cancer
Objective: To investigate the levels of plasma exosome-derived fragile-site associated tumor suppressor (FATS) and evaluate its predictive ability in ovarian cancer (OC) patients. Patients and Methods: Exosome-rich fractions were isolated from the plasma of enrolled 90 patients with OC. The levels of plasma exosome-derived FATS were detected with ELISA. Results: The levels of exosome-derived FATS in OC patient were significantly lower than in healthy controls (P < 0.001). The levels of plasma exosome-derived FATS were obviously higher in OC patients with low grade (1/2), FIGO stages I/II than high grade (3/4), stages III/ IV disease (P = 0.003; P < 0.001). The levels of plasma exosome-derived FATS were significantly higher in OC patients with no lymph node metastasis, no ascites than those with lymph node metastasis, ascites (both P < 0.001). The levels of plasma exosome-derived FATS were obviously higher in OC patients with CA-125 less than 35U/ml than more than 35U/ml (P < 0.001). Among all enrolled OC patients, both 5-DFS and 5-OS were shorter in patients who had low plasma exosome-derived FATS levels than that high levels (both P < 0.001). The AUROC of plasma exosome-derived FATS were 0.85(95% CI: 0.76-0.91) for 5-DFS, 0.91(95% CI: 0.83-0.96) for 5-OS prediction in patients with OC, respectively. Conclusions: Plasma exosome-derived FATS levels in OC patient were significantly down-regulated. Low levels of plasma exosome-derived FATS had close relationship with FIGO stages I/II, low grade, ascites, higher levels of CA-125, lymph node metastasis and prognosis of OC patients. Our findings may provide a new strategy in treating OC.
- Open Access
- 1 January 2021
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 12 (5) , 1538-1547
Plasma exosome-derived B-cell translation gene 1: a predictive marker for the prognosis in patients with non-small cell lung cancer
Objective: In this study, we wanted to investigate the plasma exosome-derived B-cell translocation gene 1 (BTG-1) level as a predictive marker for the prognosis in patients with Non-small cell lung cancer (NSCLC).
- 1 January 2021
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 12 (5) , 1538-1547
Open AccessPlasma exosome-derived B-cell translation gene 1: a predictive marker for the prognosis in patients with non-small cell lung cancer
Objective: In this study, we wanted to investigate the plasma exosome-derived B-cell translocation gene 1 (BTG-1) level as a predictive marker for the prognosis in patients with Non-small cell lung cancer (NSCLC).
- Open Access
- 5 June 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (23) , e20638
Red cell distribution width-to-lymphocyte ratio
To evaluate the diagnostic power of red cell distribution width-to-lymphocyte ratio (RLR) for HBV-related liver cirrhosis via a retrospective cohort study. Seven hundred fifty healthy controls, 327 chronic hepatitis B (CHB) patients, and 410 patients with HBV-related liver cirrhosis (HBV-LC) were enrolled in this study. RLR, lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR), red cell distribution width (RDW), AST to platelet ratio index (APRI), and fibrosis index based on the 4 factors (FIB-4) were compared between the 3 groups. The predictive powers of RLR and RDW for HBV-related liver cirrhosis and patient prognosis were evaluated using AUROC. Patients with HBV-related liver cirrhosis had higher RLR, FIB-4, NLR, RDW, APRI, and lower LMR compared with the control and CHB groups. RLR in the HBV-LC group was significantly higher than both CHB and control groups (both P < .05). While RLR in the CHB group was also higher than the control group, the difference was not statistically significant (P > .05). The AUROC of RLR for predicting HBV-related liver cirrhosis was 0.87, and was superior to RDW (0.81), FIB-4 (0.79), and APRI (0.60). With an optimized cut-off value (10.87), RLR had the highest sensitivity (0.88) and specificity (0.72), and was superior to RDW (0.86, 0.64), FIB-4 (0.80, 0.65), and APRI (0.85, 0.48) as a biomarker. For all 3 groups, RLR was negatively correlated (all P < .05) with serum platelet (PLT) and was positively correlated (all P < .05) with FIB-4 and APRI. There was no significant statistical difference in RLR for patients in HBV-LC group who had different prognosis (P > .05). The RLR, a routinely available, inexpensive, and easily calculated measure, can be used as a predictor of HBV-related liver cirrhosis, but not as a predictor of prognosis for patients with liver cirrhosis. Use of RLR may reduce the need for frequent liver biopsies in CHB patients.
- 5 June 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (23) , e20638
Open AccessRed cell distribution width-to-lymphocyte ratio
To evaluate the diagnostic power of red cell distribution width-to-lymphocyte ratio (RLR) for HBV-related liver cirrhosis via a retrospective cohort study. Seven hundred fifty healthy controls, 327 chronic hepatitis B (CHB) patients, and 410 patients with HBV-related liver cirrhosis (HBV-LC) were enrolled in this study. RLR, lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR), red cell distribution width (RDW), AST to platelet ratio index (APRI), and fibrosis index based on the 4 factors (FIB-4) were compared between the 3 groups. The predictive powers of RLR and RDW for HBV-related liver cirrhosis and patient prognosis were evaluated using AUROC. Patients with HBV-related liver cirrhosis had higher RLR, FIB-4, NLR, RDW, APRI, and lower LMR compared with the control and CHB groups. RLR in the HBV-LC group was significantly higher than both CHB and control groups (both P < .05). While RLR in the CHB group was also higher than the control group, the difference was not statistically significant (P > .05). The AUROC of RLR for predicting HBV-related liver cirrhosis was 0.87, and was superior to RDW (0.81), FIB-4 (0.79), and APRI (0.60). With an optimized cut-off value (10.87), RLR had the highest sensitivity (0.88) and specificity (0.72), and was superior to RDW (0.86, 0.64), FIB-4 (0.80, 0.65), and APRI (0.85, 0.48) as a biomarker. For all 3 groups, RLR was negatively correlated (all P < .05) with serum platelet (PLT) and was positively correlated (all P < .05) with FIB-4 and APRI. There was no significant statistical difference in RLR for patients in HBV-LC group who had different prognosis (P > .05). The RLR, a routinely available, inexpensive, and easily calculated measure, can be used as a predictor of HBV-related liver cirrhosis, but not as a predictor of prognosis for patients with liver cirrhosis. Use of RLR may reduce the need for frequent liver biopsies in CHB patients.
- Open Access
- 15 May 2020
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 20 (2) , 1105-1114
Neutrophil‑to‑lymphocyte ratio and red blood cell distribution width‑to‑platelet ratio predict cardiovascular events in hemodialysis patients
Cardiovascular diseases are among the primary causes of decreased quality of life as well as mortality of hemodialysis patients with end‑stage renal disease. The aim of the present study was to evaluate the predictive value of the red blood cell distribution width (RDW)‑to‑platelet ratio (RPR) and neutrophil‑to‑lymphocyte ratio (NLR) regarding the occurrence or development of cardiovascular events in hemodialysis patients, as well as the prognostic value of this metric. A total of 219 hemodialysis patients with cardiovascular events (HCE group) and 276 hemodialysis patients with no cardiovascular events (HNCE group) were enrolled in the present study. The clinical characteristics and laboratory parameters on admission, including RDW, as well as neutrophil, lymphocyte and platelet counts, were recorded. The NLR and RPR were increased in the HCE group compared with those in the HNCE group and there was a positive association between the NLR or RPR and the incidence of cardiovascular events in hemodialysis patients. In the receiver operating characteristics curve analysis, the area under the curve of the RPR for predicting cardiovascular events in hemodialysis patients was 0.88, while that for the NLR was 0.84. The sensitivity and specificity of the RPR for predicting cardiovascular events in hemodialysis patients were 0.87 and 0.82 respectively, and for the NLR, they were 0.75 and 0.79, respectively. The RPR was an independent risk factor for the prognosis regarding cardiovascular events in hemodialysis patients. In addition, the NLR and RPR were correlated with brain natriuretic peptide (BNP), cardiac troponin I (cTnI), creatine kinase isoenzyme‑MB (CK‑MB), and associated with ST segment changes in HCE patients. In conclusion, it was possible to predict the incidence of cardiovascular events in hemodialysis patients using the NLR and RPR, while the RPR had a better sensitivity and specificity than the NLR. The RPR was an independent risk factor for the prognosis regarding cardiovascular events in hemodialysis patients. These routinely available parameters should be considered as novel diagnostic markers for the occurrence and development of cardiovascular events in hemodialysis patients and their prognosis.
- 15 May 2020
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 20 (2) , 1105-1114
Open AccessNeutrophil‑to‑lymphocyte ratio and red blood cell distribution width‑to‑platelet ratio predict cardiovascular events in hemodialysis patients
Cardiovascular diseases are among the primary causes of decreased quality of life as well as mortality of hemodialysis patients with end‑stage renal disease. The aim of the present study was to evaluate the predictive value of the red blood cell distribution width (RDW)‑to‑platelet ratio (RPR) and neutrophil‑to‑lymphocyte ratio (NLR) regarding the occurrence or development of cardiovascular events in hemodialysis patients, as well as the prognostic value of this metric. A total of 219 hemodialysis patients with cardiovascular events (HCE group) and 276 hemodialysis patients with no cardiovascular events (HNCE group) were enrolled in the present study. The clinical characteristics and laboratory parameters on admission, including RDW, as well as neutrophil, lymphocyte and platelet counts, were recorded. The NLR and RPR were increased in the HCE group compared with those in the HNCE group and there was a positive association between the NLR or RPR and the incidence of cardiovascular events in hemodialysis patients. In the receiver operating characteristics curve analysis, the area under the curve of the RPR for predicting cardiovascular events in hemodialysis patients was 0.88, while that for the NLR was 0.84. The sensitivity and specificity of the RPR for predicting cardiovascular events in hemodialysis patients were 0.87 and 0.82 respectively, and for the NLR, they were 0.75 and 0.79, respectively. The RPR was an independent risk factor for the prognosis regarding cardiovascular events in hemodialysis patients. In addition, the NLR and RPR were correlated with brain natriuretic peptide (BNP), cardiac troponin I (cTnI), creatine kinase isoenzyme‑MB (CK‑MB), and associated with ST segment changes in HCE patients. In conclusion, it was possible to predict the incidence of cardiovascular events in hemodialysis patients using the NLR and RPR, while the RPR had a better sensitivity and specificity than the NLR. The RPR was an independent risk factor for the prognosis regarding cardiovascular events in hemodialysis patients. These routinely available parameters should be considered as novel diagnostic markers for the occurrence and development of cardiovascular events in hemodialysis patients and their prognosis.
- 13 May 2020
- Published by Springer Nature in Journal of Biosciences
- Vol. 45 (1) , 1-10
Prognostic significance of low expression of B-cell translocation gene 1 (BTG 1) in skin squamous cell carcinoma
Although the B-cell translocation gene 1 (BTG1) plays an important role in apoptosis and negatively regulates cell proliferation, BTG1 expression in skin squamous cell carcinoma (SCC) has not been reported. In this study, we wanted to investigate the significance of BTG1 expression in SCC and adjacent tissues. The expression of BTG1 protein and mRNA in SCC tissues and adjacent tissues were detected by immunohistochemistry technique (IHC), Western blot and reverse transcriptase-polymerase chain reaction (RT-PCR). IHC staining showed that the positive expression rate of BTG1 protein in SCC tissues was 54.00%; and the positive rate was 90.50% in the adjacent tissues. Western blot showed that the expression of BTG1 protein in SCC tissues was significantly lower than that in the adjacent tissues (PBTG1 mRNA in SCC was 50.50%, which was significantly lower than that in adjacent tissues 89.00% (PBTG1 mRNA and protein expression are related to tumor diameter, stage, tumor metastasis and the degree of tumor differentiation in SCC. Patients exhibiting lower BTG1 protein expression in the SCC tissues had a significantly shorter disease-specific survival rate. BTG1 protein expression, tumor diameter, tumors site and stage were independent factors affecting the overall survival of postoperative patients. Further, BTG1 overexpression inhibited A431 cell proliferation ability, while BTG silencing enhanced A431 cell proliferation ability. The lower expression of BTG1 in SCC may be associated with the occurrence, development and prognosis of SCC.
- 13 May 2020
- Published by Springer Nature in Journal of Biosciences
- Vol. 45 (1) , 1-10
Prognostic significance of low expression of B-cell translocation gene 1 (BTG 1) in skin squamous cell carcinoma
Although the B-cell translocation gene 1 (BTG1) plays an important role in apoptosis and negatively regulates cell proliferation, BTG1 expression in skin squamous cell carcinoma (SCC) has not been reported. In this study, we wanted to investigate the significance of BTG1 expression in SCC and adjacent tissues. The expression of BTG1 protein and mRNA in SCC tissues and adjacent tissues were detected by immunohistochemistry technique (IHC), Western blot and reverse transcriptase-polymerase chain reaction (RT-PCR). IHC staining showed that the positive expression rate of BTG1 protein in SCC tissues was 54.00%; and the positive rate was 90.50% in the adjacent tissues. Western blot showed that the expression of BTG1 protein in SCC tissues was significantly lower than that in the adjacent tissues (PBTG1 mRNA in SCC was 50.50%, which was significantly lower than that in adjacent tissues 89.00% (PBTG1 mRNA and protein expression are related to tumor diameter, stage, tumor metastasis and the degree of tumor differentiation in SCC. Patients exhibiting lower BTG1 protein expression in the SCC tissues had a significantly shorter disease-specific survival rate. BTG1 protein expression, tumor diameter, tumors site and stage were independent factors affecting the overall survival of postoperative patients. Further, BTG1 overexpression inhibited A431 cell proliferation ability, while BTG silencing enhanced A431 cell proliferation ability. The lower expression of BTG1 in SCC may be associated with the occurrence, development and prognosis of SCC.
- Open Access
- 1 April 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (16) , e19755
Clinical significance of high expression of proliferating cell nuclear antigen in non-small cell lung cancer
Although proliferating cell nuclear antigen (PCNA) plays an important role in tumor proliferation and its expression level is closely related to the biological activity of tumor cells, PCNA expression in non-small cell lung cancer (NSCLC) has been seldom reported. In this study, we aimed to investigate the significance of PCNA expression in NSCLC tissues. PCNA expression in NSCLC and adjacent tissues were assessed by immunohistochemistry (IHC), western blotting, and reverse transcription polymerase chain reaction. Single factor analysis was used to study the relationship between the expression of PCNA and clinicopathological features of NSCLC. Multi-factor Cox survival analysis was used to evaluate the relationship between the expression of PCNA and overall survival of postoperative NSCLC patients. The areas under the receiver operating characteristics were calculated to evaluate the value of PCNA expression level in predicting the 3-year survival of NSCLC patients. IHC analysis showed that the positive expression rates of PCNA protein in NSCLC and adjacent tissues were 91.79% (257/280) and 25.83% (31/120), respectively. Western blotting confirmed that PCNA protein level was significantly higher in NSCLC tissues than in the adjacent tissues (P < .05). Reverse transcription polymerase chain reaction showed that the positive rate of PCNA mRNA in NSCLC was 88.93% (249/280), which was significantly higher than that in adjacent tissues 29.17% (35/120) (P < .05). Both PCNA mRNA and protein levels were correlated with tumor differentiation, size, metastasis, and stage in NSCLC. Patients exhibiting higher PCNA protein expression had a significantly shorter disease-specific survival rate than the other patients. PCNA protein level and tumor pathological type, metastasis, differentiation degree, and stage were independent factors affecting the overall survival of postoperative patients. The areas under the receiver operating characteristics of PCNA mRNA for predicting the 3-year survival of NSCLC patients was 0.89 (0.79–0.98), with a sensitivity and specificity of 0.84 and 0.76, respectively. In conclusion, high PCNA protein and mRNA levels may be associated with the occurrence, development, and prognosis of NSCLC.
- 1 April 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (16) , e19755
Open AccessClinical significance of high expression of proliferating cell nuclear antigen in non-small cell lung cancer
Although proliferating cell nuclear antigen (PCNA) plays an important role in tumor proliferation and its expression level is closely related to the biological activity of tumor cells, PCNA expression in non-small cell lung cancer (NSCLC) has been seldom reported. In this study, we aimed to investigate the significance of PCNA expression in NSCLC tissues. PCNA expression in NSCLC and adjacent tissues were assessed by immunohistochemistry (IHC), western blotting, and reverse transcription polymerase chain reaction. Single factor analysis was used to study the relationship between the expression of PCNA and clinicopathological features of NSCLC. Multi-factor Cox survival analysis was used to evaluate the relationship between the expression of PCNA and overall survival of postoperative NSCLC patients. The areas under the receiver operating characteristics were calculated to evaluate the value of PCNA expression level in predicting the 3-year survival of NSCLC patients. IHC analysis showed that the positive expression rates of PCNA protein in NSCLC and adjacent tissues were 91.79% (257/280) and 25.83% (31/120), respectively. Western blotting confirmed that PCNA protein level was significantly higher in NSCLC tissues than in the adjacent tissues (P < .05). Reverse transcription polymerase chain reaction showed that the positive rate of PCNA mRNA in NSCLC was 88.93% (249/280), which was significantly higher than that in adjacent tissues 29.17% (35/120) (P < .05). Both PCNA mRNA and protein levels were correlated with tumor differentiation, size, metastasis, and stage in NSCLC. Patients exhibiting higher PCNA protein expression had a significantly shorter disease-specific survival rate than the other patients. PCNA protein level and tumor pathological type, metastasis, differentiation degree, and stage were independent factors affecting the overall survival of postoperative patients. The areas under the receiver operating characteristics of PCNA mRNA for predicting the 3-year survival of NSCLC patients was 0.89 (0.79–0.98), with a sensitivity and specificity of 0.84 and 0.76, respectively. In conclusion, high PCNA protein and mRNA levels may be associated with the occurrence, development, and prognosis of NSCLC.